Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week. While health care doesn’t seem to be anywhere near the topic of debate ahead of this election season, it has the potential to be hugely affected by whatever party takes power in the United States.
For the other notable earnings this week, check out the Dow Jones industrials earnings and other major earnings previews.
Note that the earnings and revenue estimates may change ahead of the formal reports, and some companies may reschedule reporting dates as well.
Biogen Inc. (NASDAQ: BIIB) is set to report its most recent results on Tuesday. The consensus estimates from Thomson Reuters call for earnings per share (EPS) of $6.78 and $3.33 billion in revenue. Shares were changing hands at $320.41 on Friday’s close. The 52-week range is $249.17 to $388.67.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is scheduled to report its third-quarter results on Wednesday. The consensus estimates are $1.74 in EPS and $1.02 billion in revenue. Shares traded at $125.89 as last week came to a close. The consensus price target is $163.41, and the 52-week trading range is $102.10 to $142.24.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is set to share its latest quarterly earnings on Thursday. The consensus estimates call for a net loss of $0.21 per share on $366.93 million in revenue. Shares were at $103.22 on Friday’s close, in a 52-week range of $75.81 to $106.74. The consensus price target is $120.05.
Bristol-Myers Squibb Co. (NYSE: BMY) is expected to reveal its third-quarter results on Thursday. The consensus forecast calls for $0.91 in EPS, as well as $5.72 billion in revenue. The stock ended last week at $54.30 per share. The consensus price target is $61.59, and the 52-week range is $49.96 to $70.05.
Celgene Corp. (NASDAQ: CELG) also will share its latest quarterly earnings on Thursday. The consensus estimates call for $2.34 in EPS and $1.74 billion in revenue. Shares were at $99.62 as Friday’s trading ended, in a 52-week range of $95.45 to $119.29. The consensus price target is $128.22.
And Gilead Sciences Inc. (NASDAQ: GILD) is expected to reveal its third-quarter results on Thursday as well. The consensus forecast calls for $1.63 in EPS, as well as $5.37 billion in revenue. The stock ended last week at $73.27 per share. The consensus price target is $87.91, and the 52-week trading range is $64.27 to $89.54.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
